Current stock page

Financial Data

ELVN Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ELVNEnliven Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$48.80+$0.49 (+1.01%)

Latest quote

  • Momentum
    66
  • Value
    —
  • Quality
    84
  • Risk resilience
    56
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0$0-$46K$0$0$0$0
Operating Income-$36.05M-$37.21M-$27.82M-$34.29M-$25.1M-$28.58M-$31.69M-$26.9M
Net Income-$27.7M-$32.49M-$23.63M-$29.67M-$20.15M-$25.34M-$28.54M-$23.18M
EPS-$0.36-$0.49-$0.38-$0.45-$0.32-$0.49-$0.57-$0.46
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$12.56M-$18.53M-$19.29M-$15.84M-$13.28M-$17.06M-$24.13M-$17.2M
Capital Expenditure-$94K-$99K$0$0$1K-$139K-$20K$0
Free Cash Flow-$12.65M-$18.63M-$19.29M-$15.84M-$13.28M-$17.2M-$24.15M-$17.2M
Net Cash Provided By Operating Activities-$12.56M-$18.53M-$19.29M-$15.84M-$13.28M-$17.06M-$24.13M-$17.2M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$897.23M$910.22M$464.85M$476.17M$490.88M$503.89M$302.57M$325.76M
Total Debt$1.32M$1.51M$302K$399K$387K$580K$365K$0
Cash And Cash Equivalents$151.67M$135.51M$132.18M$98.9M$101.73M$119.44M$101.71M$124.12M
Total Liabilities$20.28M$15.07M$11.49M$16.57M$14.75M$15.42M$14.27M$15.92M
Total Stockholders Equity$876.95M$895.15M$453.37M$459.6M$476.12M$488.47M$288.3M$309.85M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.44.415.583.542.652.133.453.26
P/S ratio————————
Debt To Equity00000000
Free Cash Flow Yield-1.72%-1.70%-2.59%-4.33%-5.70%-6.80%-7.43%-7.24%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.44.415.583.542.652.133.453.26
P/S ratio————————
Return On Equity-12.94%-11.83%-21.79%-22.56%-20.42%-20.52%-32.89%-28.73%
Debt To Equity00000000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-29.05x
Pb4.34x
EPS Growth Yoy-12.50%
Gross Margin0.00%
Operating Margin0.00%
ROE-16.91%
ROIC-15.41%
Debt To Equity0
FCF Yield-1.85%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$48.80
Volume972,567
RSI (14)57.32
MACD1.37
MACD signal0.59
MACD histogram0.78
ADX (14)27.8
SMA (50)$46.43
SMA (200)$43.83
ATR (14)$2.26
Historical volatility (annualized)60.29%
Volume (20-day average)1.59M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score56/100
Beta1.1
Annual volatility78.19%
Max Drawdown-38.97%
Sharpe Ratio1.43
VaR (95%, 1-day)-5.23%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ELVN Financial Data FAQ

What is Enliven Therapeutics, Inc.'s revenue?

Enliven Therapeutics, Inc.'s revenue is one of the core financial data points for ELVN. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Enliven Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Enliven Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ELVN's EPS?

ELVN's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Enliven Therapeutics, Inc.'s net income?

Enliven Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Enliven Therapeutics, Inc. generate?

Free cash flow shows how much cash Enliven Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Enliven Therapeutics, Inc. have?

Cash and debt help frame ELVN's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.